C-Reactive Protein/Albumin Ratio and Acne Vulgaris
- Disease/Condition
- Acne Vulgaris
- Drug/Device/Intervention
- Biochemical blood analysis
- Study type
- Observational
- Intervention type
- diagnostic test
- Primary sponsor
- Ataturk University
- Location
- Erzurum, Turkey
- Phase
- N/A
- Start date
- Jan 05, 2022
- End date
- May 01, 2023
- Enrollment
- 96 participants
CRP/albumin ratio
Objective: Acne vulgaris, an inflammatory disease, was investigated in this study with the
 claim that C-reactive protein (CRP) / albumin ratio and some hematological parameter ratios
 have the potential to be used as inflammatory markers to monitor disease severity and
 prognosis.
 
 Methods: A descriptive cross-sectional study was conducted with two groups of patients aged
 18-65 years, 61 patients diagnosed with acne vulgaris and 35 healthy control patients, and
 routine hemogram and biochemical parameters were compared. The Global Acne Severity Index was
 used to determine the severity of acne vulgaris.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06004583
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06004583 through Pure Global AI's free database. This phase not specified trial is sponsored by Ataturk University and is currently Completed. The study focuses on Acne Vulgaris. Target enrollment is 96 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.